Hepagene

Hepagene.com

ABOUT HEPAGENE

Non-alcoholic Steatohepatitis (NASH)

Chronic Hepatitis B Infection (HBV)

PIPELINE

Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH

About HPG1860

About NASH

About Hepagene Therapeutics, Inc

MANAGEMENT TEAM

MANAGEMENT TEAM

CEO - Dr. Michael X. Xu
Seasoned serial entrepreneur; 20+ years in liver diseases/pharma; 50+ publications and patent applications
Prior: Enantigen, JNJ, NYU Ph.D.

CMO - Dr. Roger Liu
20 years of clinical dev in MASH/PBC/PSC/CVD, rare and metabolic diseases, a physician-executive
Prior: Allergan, Arena (acquired by Pfizer), Takeda, Ionis University of Alberta Ph.D.

CFO – Bing Lin, MBA/CPA
Harvard MBA, CPA, 20+ years public market experiences at major asset management firms and hedge funds
Ex-Chairman/CEO of a listed company in Nasdaq
Ex-Audit Committee Chairman of an HK listed company